Page 466 - Essential Haematology

452 / Index

therapy-related myeloid neoplasms toxin-induced 334 tirofiban, venous thrombosis 379
(t-AML) 179, 180 viral infections 390 tissue factor (TF) 321, 322–3
thrombasthenia 340–1 see also disseminated intravascular disseminated intravascular
thrombin 321, 322 coagulation (DIC); coagulation 356
direct inhibitors 376 thrombotic synthesis 324
disseminated intravascular thrombocytopenic tissue factor pathway inhibitor
coagulation 356 purpura (TFPI) 321, 323, 325
generation 322, 323, 325 thrombocytopenic purpura, tissue hypoxia 17–18
inactivation 325 autoimmune 138 tissue plasminogen activator (t-PA)
thrombin-activated fi brinolysis thrombocytosis, post-splenectomy 324, 377–8
inhibitor (TAFI) 326 369 fi brinolysis 326
thrombin time (TT) 327, 328 thromboelastography (TEG) 359, inactivation 326
neonates 418 360 total iron-binding capacity (TIBC)
thrombophilia screening 370 thrombolytic therapy 377–8 42, 43
thrombocytopenia 333–40 contraindications 378 iron overload 53
ALL 224 thrombomimetics, idiopathic normal values 425
AML 181 thrombocytopenic toxoplasma/toxoplasmosis
antiphospholipid syndrome purpura 343 glandular fever 135
369–70 thrombomodulin 325 haematological changes 391
causes 334 thrombophilia, investigations 370 tranexamic acid 332
diagnosis 342–3 thromboplastin 343 von Willebrand disease 353
disseminated intravascular thrombopoietin (TPO) 7, 8 transcobalamin/transcobalamin
coagulation 338 platelet production regulation defi ciency 60
drug-induced 334, 337, 338 316 transcription factors 8, 10, 13
fetomaternal alloimmune 418 thrombopoietin receptor agonists activation/DNA-binding domain
giant cavernous haemangioma 336 13
331 thrombosis 363 transferrin 34
haemolytic uraemic syndrome arterial 363–4 percentage saturation 51
337, 338 antithrombin defi ciency 367 transferrin receptor 1 (TfR1) 34
haemostatic function tests 327 disseminated intravascular synthesis regulation 35–7
heparin-induced 373–4 coagulation 358 transferrin receptor 2 (TfR2) 37,
hypertensive disorders 415 hereditary disorders of 38
immune complex-mediated haemostasis 364–8 gene mutations 53
387 pregnancy 416 transforming growth factor β
immune in CLL 237 thrombophilia investigations 370 (TGF-β) 8
infections 337 see also venous thrombosis transfusion related acute lung injury
liver disease 355, 388 thrombotic thrombocytopenic (TRALI) 408
malaria 391 purpura 85, 337–8, 339, trimethoprim 63, 71
massive transfusion syndrome 340 tropical splenomegaly syndrome
340 thromboxane A 2 (TXA 2) 320, 325 144–6, 391
platelets synthesis 319 trypanosomiasis 391, 394
increased destruction 334–40 vasoconstriction 324 tuberculosis, leukaemoid reaction
production failure 333–4 thrombus/thrombus formation 363 388
transfusions 343 thymoma, red cell aplasia 294 tumour lysis syndrome 168
post-transfusion purpura 337 thymus tumour necrosis factor (TNF) 392
pregnancy 414, 415–16 ALL 225, 226 tumour suppressor genes 154, 155
refractory 215 aplasia 139 tyrosine kinase 155
splenic pooling increase 339 thyroxine 388 tyrosine kinase inhibitors